Galecto, Inc. (GLTO)

$ 4.28
-0.05 (-1.15%)
Symbol GLTO
Price $ 4.28
Beta 0.000
Volume Avg. 1.19M
Market Cap 0.11B
Shares () -
52 Week Range 4.03-17.99
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -38.26% Strong Sell
ROA -26.79% Sell
Operating Margin -
Debt / Equity 3.99% Neutral
P/E -
P/B 0.71 Buy


Consensus EPS

Upgrades & Downgrades


Dr. Hans T. Schambye

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.